Unassociated Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):
 
June 25, 2007
 
GENEREX BIOTECHNOLOGY CORPORATION
(Exact name of registrant as specified in its charter)
 
Delaware
000-29169
98-0178636
(State or other jurisdiction of
incorporation)
(Commission File Number)
(I.R.S Employer Identification No.)
 
33 Harbour Square, Suite 202, Toronto, Ontario Canada
  
M5J 2G2
(Address of principal executive offices)
  
(Zip Code)
 
Registrant’s telephone number, including area code: (416) 364-2551
 
N/A
(Former name or former address, if changed since last report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
Item 8.01 Other Events.

On June 25, 2007, Generex Biotechnology Corporation (the “Company”) issued a press release announcing preparations to commence a Phase III clinical trial of Generex Oral-lyn, the Company’s proprietary oral insulin spray product. A copy of the press release is attached as Exhibit 99.1, and the information in Exhibit 99.1 is incorporated herein by reference.
 
Item 9.01 Financial Statements and Exhibits.
 
(d)
Exhibits. 
 
     
Exhibit
Number
  
Description
99.1
  
Press Release, dated June 25, 2007.
 
 
 
 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
  
 
GENEREX BIOTECHNOLOGY CORPORATION.
     
Date: June 25, 2007
 
  
 
/s/ Rose C. Perri
 
 
  
 
  
 
Chief Operating Officer and Chief Financial Officer
(principal financial officer)

 
 
 

EXHIBIT INDEX
 
     
Exhibit
Number
  
Description
   
99.1
  
Press Release, dated June 25, 2007.